Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
3 participants
INTERVENTIONAL
2015-10-31
2016-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Loop Drainage Versus Incision and Drainage for Abscesses in Children
NCT02443272
Loop Drainage Versus Incision and Drainage for Abscesses
NCT03911518
Loop Drainage: Effectiveness in Treating Cutaneous Abscesses
NCT02697279
The LOOP Trial in Treatment of Skin Abscesses
NCT03398746
Incision and Loop Drainage Utilizing a Novel Technique for Management of Cutaneous Abscess in an Adult Population
NCT04241471
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Standardized I\&D will be performed with a #11 blade scalpel and a full thickness cut incising the lesion along at least 50% of the abscess diameter. The pocket will then be probed to break up septations and the residual cavity will be irrigated with normal saline. Iodinated gauze 0.25 inch will be used to loosely pack the remaining cavity if the physician deems packing is necessary. The gauze will be left trailing out of the surgical incision. The abscess will then be covered with 4 X 4 dry gauze and taped in place.
* Minimally invasive I\&D with vessel loop will be preformed by making a 5mm incision with a #11 blade in the area of maximal fluctuance. The cavity will then be probed with forceps breaking up any septations. The forceps will then be used to find the furthest extent of the cavity, and the #11 blade will be used to make a 5mm incision at the tip of the forceps (at the farthest extent of the cavity). The forceps will then be pushed through this second incision. The vessel loop will be grasped by the forceps and then pulled back through both surgical incisions. The vessel loop will then be tied loosely together, creating a loop back through both surgical incisions. Both sides of the incisions will then be irrigated with normal saline.
Cultures will be obtained, if possible, from the abscess. Pain medication and sedation at the time of the I\&D will be left to the discretion of the treating physician. Antibiotics will not be mandated, but allowed at the judgment of the treating medical team. All subjects will be given 2 prescriptions for analgesia at home. One for mild pain, ibuprofen; another for moderate or severe pain, acetaminophen with hydrocodone (either liquid or pills) will be given. Equipotent alternatives will be provided in case of medication allergy. Pain scores will be assessed using a ten point scale before and after the procedure and at 48 hour follow up. Data recorded at the first visit will include demographics (age, male/female), characteristics of the abscess, fever, duration of symptoms, history of prior abscess, antibiotics in the last month, and provision of antibiotics post-procedure.
All subjects will return to the ER in 72 hours and 1 week for a recheck. At the 3rd day visit, wound packing will be removed. Large cavities will be repacked at the discretion of the ED physician. Loops will be cut and removed at the 7th day visit unless significant cellulitis remains. If cellulitis remains after 7 days, additional visits/hospitalization would be set up at the treating doctors discretion. Given that failure of treatment is a possible event in any abscess drainage, even those not involved with this study, hospitalization or additional visits beyond the 2 included in the study, will be billed to the patient's family and/or insurance company as any visit to the ER or hospital admission.
Patients and families will also be contacted at one month via telephone interview. Self-rated cosmetic outcome will be assessed using a 10 point scale from worst to best looking scar.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Traditional
cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
traditional I&D with or without packing
abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
Minimally Invasive
Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
vessel loop
using the vessel loop to hold the place of the surgical wound that is made during I\&D
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vessel loop
using the vessel loop to hold the place of the surgical wound that is made during I\&D
traditional I&D with or without packing
abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* immunocompromised
* cancer
* chemotherapy
* requires hospitalization for treatment of abscess
* abscess felt not drainable in the ER by ER physicians
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Milan Nadkarni, MD
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00033369
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.